Literature DB >> 12569593

A 5-decade analysis of 13,715 carcinoid tumors.

Irvin M Modlin1, Kevin D Lye, Mark Kidd.   

Abstract

BACKGROUND: Carcinoid tumors represent an unusual and complex disease spectrum with protean clinical manifestations. This compilation of several large United States-based databases comprising patients from 1950 to 1999 examines 13,715 carcinoid tumors and provides epidemiologic information regarding the natural history and evolution of the detection and diagnosis of this entity.
METHODS: The authors evaluated 10,878 carcinoid tumors that were identified by the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (NCI) from 1973 to 1999 in addition to 2837 carcinoid tumors that were registered previously by two earlier NCI programs. To the authors' knowledge, this represents the largest current epidemiology series addressing carcinoid tumors to date.
RESULTS: Specific trends in incidence for carcinoid tumors of certain sites were identified. Among the most recently collected subset of data, sites that demonstrated the greatest incidence of carcinoids were the gastrointestinal tract (67.5%) and the bronchopulmonary system (25.3%). Within the gastrointestinal tract, most carcinoid tumors occurred in the small intestine (41.8%), rectum (27.4%), and stomach (8.7%). For all sites, age-adjusted incidence rates were highest in black males (4.48 per 100,000 population per year). Associated noncarcinoid tumors were frequent in conjunction with small intestinal (29.0%), gastric (20.5%), colonic (20.0%), and appendiceal (18.2%) carcinoids. The highest percentages of nonlocalized lesions were noted for cecal (81.5-83.2%) and pancreatic (71.9-81.3%) carcinoids, whereas the highest percentage of localized disease was found among rectal (81.7%), gastric (67.5%), and bronchopulmonary (65.4%) carcinoids. The best 5-year survival rates were recorded for patients with rectal (88.3%), bronchopulmonary (73.5%), and appendiceal (71.0%) carcinoids; these tumors exhibited invasive growth or metastatic spread in 3.9%, 27.5%, and 38.8% of patients, respectively.
CONCLUSIONS: Carcinoids appear to have increased in overall incidence over the past 30 years; for some sites, this trend has been evident for nearly half a century. Recent marked increases in gastric and rectal carcinoids and a concomitant decrease in appendiceal carcinoid incidence may be due in part to varying rules of registration among the compiled databases examined in this report or to improvements in diagnostic technology; increased awareness of and about carcinoid tumors also may play a significant role. In 12.9% of all patients with carcinoid, distant metastases already were evident at the time of diagnosis; the overall 5-year survival rate for all carcinoid tumors, regardless of site, was 67.2%. These findings bring into question the widely promulgated relative benignity of carcinoid disease. Certain carcinoid tumors, such as those of the rectum, appear to be over-represented among the black and Asian populations within the United States, suggesting the role of genetics in the development of this intriguing disease. Copyright 2003 American Cancer Society

Entities:  

Mesh:

Year:  2003        PMID: 12569593     DOI: 10.1002/cncr.11105

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  731 in total

1.  Prevalence of Small Intestine Carcinoid Tumors: A US Population-Based Study 2012-2017.

Authors:  Mohannad Abou Saleh; Emad Mansoor; Mohammad Anindo; Gerard Isenberg
Journal:  Dig Dis Sci       Date:  2018-12-05       Impact factor: 3.199

Review 2.  The European Society of Thoracic Surgeons (ESTS) lung neuroendocrine tumors (NETs) database.

Authors:  Pier Luigi Filosso; Pierre Emmanuel Falcoz; Paolo Solidoro; Danilo Pellicano; Stefano Passani; Francesco Guerrera; Enrico Ruffini
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

3.  [Neuroendocrine carcinoma of the lung: a diagnostic and therapeutic challenge].

Authors:  Claudia Böttger; Arne Warth; Peter P Nawroth; Berend Isermann
Journal:  Med Klin (Munich)       Date:  2010-04

4.  [Fulminant duodenal bleeding as first manifestation of a neuroendocrine carcinoma of the pancreatic head].

Authors:  Kerstin Schütte; Jan Bornschein; Doerthe Kuester; Gero Wieners; Peter Malfertheiner
Journal:  Med Klin (Munich)       Date:  2010-04

5.  Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience.

Authors:  William C Chen; Richard R P Warner; Stephen C Ward; Noam Harpaz; Celia M Divino; Steven H Itzkowitz; Michelle K Kim
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

6.  A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma.

Authors:  Tabraiz A Mohammed; Kyle D Holen; Renata Jaskula-Sztul; Daniel Mulkerin; Sam J Lubner; William R Schelman; Jens Eickhoff; Herbert Chen; Noelle K Loconte
Journal:  Oncologist       Date:  2011-05-31

7.  Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor.

Authors:  Ryoichi Iwata; Masato Maruyama; Tomoki Ito; Yosuke Nakano; Yonehiro Kanemura; Taro Koike; Souichi Oe; Kunikazu Yoshimura; Masahiro Nonaka; Shosaku Nomura; Tetsuo Sugimoto; Hisao Yamada; Akio Asai
Journal:  Med Mol Morphol       Date:  2017-05-17       Impact factor: 2.309

8.  Duodenal and Ampullary Carcinoid Tumors: Size Predicts Necessity for Lymphadenectomy.

Authors:  Epameinondas Dogeas; John L Cameron; Cristopher L Wolfgang; Kenzo Hirose; Ralph H Hruban; Martin A Makary; Timothy A Pawlik; Michael A Choti
Journal:  J Gastrointest Surg       Date:  2017-05-17       Impact factor: 3.452

9.  Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient.

Authors:  Manuel Weber; Lukas Kessler; Benedikt Schaarschmidt; Wolfgang Peter Fendler; Harald Lahner; Gerald Antoch; Lale Umutlu; Ken Herrmann; Christoph Rischpler
Journal:  BMC Cancer       Date:  2020-04-16       Impact factor: 4.430

Review 10.  Rectal carcinoids: a systematic review.

Authors:  Frank D McDermott; Anna Heeney; Danielle Courtney; Helen Mohan; Des Winter
Journal:  Surg Endosc       Date:  2014-03-01       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.